Navigation Links
MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010
Date:2/22/2011

WARREN, N.J., Feb. 22, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, today announced that Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ("the Group") (LSE: RB), provided an update on U.S. market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for the treatment of opioid dependence during its announcement of full-year 2010 financial results.

Full-year 2010 net revenue for the Group's Subutex and Suboxone prescription drug business grew 24% to 737 million pounds Sterling. At the end of 2010, the market volume share for Suboxone sublingual film was 25%, and at this level would represent approximately 23% of the total U.S. net revenue for Reckitt Benckiser Pharmaceuticals Inc. (approximately 138m pounds on an annualized basis).

Suboxone sublingual film was developed through an exclusive agreement with Reckitt Benckiser Pharmaceuticals and MonoSol Rx, utilizing MonoSol Rx's proprietary PharmFilm® technology, to deliver a convenient, quick-dissolving better tasting therapeutic dose of buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist. The drugs rapidly absorb under the tongue to ensure efficacy and compliance.

A. Mark Schobel, President and CEO of MonoSol Rx, stated, "The patients and treating physicians acceptance of Suboxone sublingual film demonstrates not only the advantages of our dosage form but also the value we create for our partners as they look to protect their product franchises following exclusivity losses.  We are very happy with the market penetration of the new Suboxone sublingual films and are looking forward to continued success in 2011 and beyond."

On October 8, 2009, Suboxone lost the U.S. exclusivity afforded by its orphan drug status. In September 2010, Reckitt-Benckiser Pharmaceuticals introduced Suboxone sublingual film, a patent-protected and patient-preferred delivery system, to address the potential loss of up to 80% of the revenues and profits of the Suboxone tablet business in the year following the launch of prospective generic competitors.

About MonoSol Rx MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone®  sublingual film, the first sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator or other specialty pharma companies that can sell-in and manage product sales and marketing.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).For existing and future partners, PharmFilm® formulations can also represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  For press releases and other company information visit www.monosolrx.com Contacts:MonoSol RxKeith Kendall, Executive Vice President(732) 564-5000The Ruth Group (on behalf of MonoSol Rx)Jason Rando (media)Tel: +1 (646) 536-7025jrando@theruthgroup.com Sara Pellegrino (investors)Tel: +1 (646) 536-7002spellegrino@theruthgroup.com  


'/>"/>
SOURCE MonoSol Rx, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
2. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
3. MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Research and Markets has announced the addition of the ... Forecast" report to their offering. ... Proton Therapy Market in Italy will ... There are currently three proton therapy centers in Italy ... Italy , the first patients were treated with proton ...
(Date:3/29/2017)... and Markets has announced the addition of the "South Korean Proton ... report to their offering. ... The South Korean Proton Therapy Market is expected to almost triple ... Therapy Market for South Korea was valued at ... plays an important role in delivering comprehensive cancer care to children and ...
(Date:3/29/2017)... HUNTINGTON BEACH, Calif. , March 29, 2017 ... treatment have recognized remote monitoring devices like  Soberlink ... monitoring.   The consensus paper, published in early ... "feasible, practical and valuable in managing patient recovery." ... published in the Journal of Addiction Medicine, detail ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, ... school and college students who have participated in the program every summer. The ... now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
(Date:3/29/2017)... ... , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is ... or without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. ... patients receive early treatment, they may achieve straight teeth with less treatment in their ...
(Date:3/29/2017)... ... , ... Curio Wellness , a premium medical cannabis brand and trusted ... management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and investment ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
Breaking Medicine News(10 mins):